The goal of this proposal is to mentor and train junior faculty investigators in laboratory and/or clinical translational cancer research. Implementation of this K12 program for the career development of laboratory-based (PhD/DVM/MD) and clinical (MD or MD/PhD) translational scientists in diverse areas of oncology will ensure a cadre of highly-trained individuals who can communicate across disciplines to drive new advancements in how we approach cancer diagnosis and management. This K12 program from The Ohio State University Comprehensive Cancer Center (OSUCCC) continues its focus on early drug development, but now also extends to cancer prevention, control and survivorship research. The OSUCCC is clearly dedicated to research education and providing outstanding career development and mentoring opportunities to promising junior faculty. The Divisions of Hematology, Medical Oncology, Radiation Oncology, and Surgical Oncology each have robust programs that are continuously recruiting new junior faculty to facilitate expansion of our cancer program. Recruitment efforts also emphasize the inclusion of women, minorities and underserved groups to increase diversity. This K12 grant fills an important need by extending research education, career development and mentoring to junior faculty interested in establishing academic research careers. It is the only OSUCCC training program dedicated solely to faculty-level career development in cancer research, and thus has no overlap with any of the OSU T32 training grants, which focus on fellows. This strategy ensures continuity in training and provides individuals a structured path to become independent clinical or translational investigators. The quality of this K12 program and its success in training cancer researchers is exemplified by the career trajectories of past trainees, their papers, grants, clinical trials and other scholarly activities that have driven new discoveries. The continued success of this program will be ensured by the overall strength and direction of the OSUCCC, as demonstrated by its recent peer review score of 10 (exceptional), financial support of this K12 program by the OSUCCC and by different Divisions and Departments, and the enormous breadth of expertise and resources available at OSU. This K12 program seeks to train two types of investigators. The first includes MD and/or PhD faculty who have outstanding basic science training and want to pursue laboratory-based investigation related to applied research in experimental therapeutics, cancer prevention, control, and survivorship. The second group includes MD or MD/PhD faculty who want to pursue clinical research in experimental therapeutics and cancer prevention, control, or survivorship. Training plans are tailored to each individual trainee to facilitate their success, with inclusion of a robust evaluation program to assess the effectiveness of the K12. The value of the OSU K12 program is best demonstrated by nearly all of the current and past K12 scholars remaining in academic medicine and moving forward as independent laboratory or clinical investigators.

Public Health Relevance

The overall goal of this renewal proposal, led by John C. Byrd, MD and William E. Carson III, MD, is to mentor and effectively train MD, PhD, DVM and MD/PhD faculty investigators with basic science and/or clinically- oriented approaches to translational research so that they may dedicate their careers to independent clinical cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA133250-12
Application #
9966882
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Damico, Mark W
Project Start
2008-09-09
Project End
2024-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
12
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Miller, Eric D; Fisher, James L; Haglund, Karl E et al. (2018) The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer. J Thorac Oncol 13:426-435
Coss, Christopher C; Clinton, Steven K; Phelps, Mitch A (2018) Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy? Clin Cancer Res 24:5787-5789
Rosko, Ashley E; Huang, Ying; Benson, Don M et al. (2018) Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. J Geriatr Oncol :
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Zhang, Jiu-Cheng; Chen, Wei-Dong; Alvarez, Jean Bustamante et al. (2018) Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacol Sin 39:1693-1698
Narayanan, Ramesh; Coss, Christopher C; Dalton, James T (2018) Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol 465:134-142
Maini, Rohit; Wong, David B; Addison, Daniel et al. (2018) Persistent Underrepresentation of Kidney Disease in Randomized, Controlled Trials of Cardiovascular Disease in the Contemporary Era. J Am Soc Nephrol 29:2782-2786
Shukuya, Takehito; Patel, Sandipkumar; Shane-Carson, Kate et al. (2018) Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy. J Thorac Oncol 13:e17-e19
Sborov, Douglas W; Canella, Alessandro; Hade, Erinn M et al. (2017) A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lymphoma 58:2310-2318
Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney et al. (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8:25942-25954

Showing the most recent 10 out of 184 publications